Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

426 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.
Alric L, Ollivier-Hourmand I, Bérard E, Hillaire S, Guillaume M, Vallet-Pichard A, Bernard-Chabert B, Loustaud-Ratti V, Bourlière M, de Ledinghen V, Fouchard-Hubert I, Canva V, Minello A, Nguyen-Khac E, Leroy V, Saadoun D, Trias D, Pol S, Kamar N. Alric L, et al. Among authors: de ledinghen v. Kidney Int. 2018 Jul;94(1):206-213. doi: 10.1016/j.kint.2018.02.019. Epub 2018 May 5. Kidney Int. 2018. PMID: 29735308 Free article.
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
de Lédinghen V, Trimoulet P, Winnock M, Bernard PH, Bourlière M, Portal I, Rémy AJ, Szostak N, Lévy S, Tran A, Abergel A, Chêne G, Fleury H, Couzigou P; French Multicenter Study Group. de Lédinghen V, et al. J Hepatol. 2002 Jun;36(6):819-26. doi: 10.1016/s0168-8278(02)00071-5. J Hepatol. 2002. PMID: 12044534 Clinical Trial.
Retreatment with interferon and ribavirin vs interferon alone according to viraemia in interferon responder-relapser hepatitis C patients: a prospective multicentre randomized controlled study.
Portal I, Bourlière M, Halfon P, De Lédinghen V, Couzigou P, Bernard PH, Blanc F, Caroli-Bosc F, Arpurt JP, Vetter D, Mathieu-Chandelier C, Chazouillères O, Thiefin G, Pol S, Sogni P, Abergel A, Bailly F, Picon M, Debonne JM, Zamora C, Alleman I, Moreau X, Doll F, Eugène C, Ducloux S, Larrey D, Ouzan D, Grimaud JC, Gouvernet J, Botti G, Gérolami V, Khiri H, Gérolami A, Gauthier AP, Botta-Fridlund D. Portal I, et al. Among authors: de ledinghen v. J Viral Hepat. 2003 May;10(3):215-23. doi: 10.1046/j.1365-2893.2003.00426.x. J Viral Hepat. 2003. PMID: 12753341 Clinical Trial.
Histological response in patients treated by interferon plus ribavirin for hepatitis C virus-related severe fibrosis.
Abergel A, Darcha C, Chevallier M, Ughetto S, Henquell C, Pol S, de Ledinghen V, Canva V, Bronowicki JP, Tran A, Martineau N, Lafeuille H, Dechelotte P, Bommelaer G, Bonny C; French Multicentre Study Group. Abergel A, et al. Among authors: de ledinghen v. Eur J Gastroenterol Hepatol. 2004 Nov;16(11):1219-27. doi: 10.1097/00042737-200411000-00022. Eur J Gastroenterol Hepatol. 2004. PMID: 15489585 Clinical Trial.
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourlière M, Zarski JP, Roudot-Thoraval F; Observational VHC4 Study Group. Roulot D, et al. Among authors: de ledinghen v. J Viral Hepat. 2007 Jul;14(7):460-7. doi: 10.1111/j.1365-2893.2006.00823.x. J Viral Hepat. 2007. PMID: 17576387
Meta-analyses of FibroTest diagnostic value in chronic liver disease.
Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, Bourliere M, Cacoub P, Messous D, Munteanu M, de Ledinghen V. Poynard T, et al. Among authors: de ledinghen v. BMC Gastroenterol. 2007 Oct 15;7:40. doi: 10.1186/1471-230X-7-40. BMC Gastroenterol. 2007. PMID: 17937811 Free PMC article.
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
Calès P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourlière M, de Muret A, Sturm N, Hunault G, Oberti F. Calès P, et al. Among authors: de muret a, de ledinghen v. Liver Int. 2008 Dec;28(10):1352-62. doi: 10.1111/j.1478-3231.2008.01789.x. Epub 2008 May 19. Liver Int. 2008. PMID: 18492022 Free PMC article.
426 results